ZVRA Zevra Therapeutics Quick Ratio

Zevra Therapeutics (ZVRA) relies on external contractors for the manufacturing and packaging of orphan drugs, focusing instead on marketing and R&D. This chart of the company's price action, where the coefficient is 5.19, demonstrates crisis resilience driven by the commercialization of unique products. High growth potential is supported by low tablet production costs and the ability to implement premium pricing power in the global market.

Quick liquidity determines a company's ability to instantaneously settle short-term obligations without liquidating inventory. This metric aggregates cash and accounts receivable, allowing the quick ratio on GURU.Markets to assess the real margin of financial strength. The curve's dynamics reflect the rate of resource consumption within the operating cycle. For Zevra Therapeutics (ZVRA), such resilience is critical, as exclusive FDA orphan drug rights guarantee a steady cash flow without pricing pressure from competitors.